Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows ...

Dyne Therapeutics, a clinical-stage company focused on therapeutics for genetically driven neuromuscular diseases, announced that it will present new clinical data from its Phase 1/2 ACHIEVE trial ...

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments.

Dyne Therapeutics, Inc. experienced a dramatic rise from $6.5 to $46 per share in 2024 followed by a sharp 45% drop to ~$24, now stabilizing at ~$34. The company's IPO in September 2020 raised $ ...

Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $47.45. The firm has a market capitalization of $1.34 billion, a P/E ratio of -3.30 and a beta of 1.19.

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...

The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD). This designation is pivotal for developing DYNE ...

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), boosting the price target to $55.00. Andrew Fein has given his Buy rating due to a ...

In this article, we are going to take a look at where Dyne Therapeutics, Inc. (NASDAQ:DYN) stands against the other rebound stocks. The United States economy is in a constant state of flux.